Abstract
An understanding of the historical paths that have lead to our current state of knowledge in the field of platelet studies can be both illuminating and inspiring. Considering that the existence and function of platelets were initially described just barely over 100 years ago it is exciting to recognize how far our knowledge has advanced in such a relatively short period of time. Within 20 years of Giulio Bizzozero's definitive description of blood platelets investigators began to develop tests that could quantitate the relationship between platelets, hemostasis and bleeding, and these tests have continued to be refined ever since. At the same time, and well before the role of platelets and antiplatelet agents in cardiovascular disease was appreciated, several clinicians started using aspirin for the prevention of heart attacks. All three of these paths of research - platelet biology, platelet function testing and antiplatelet therapies - all converge on what is arguably one of the most important questions in clinical medicine today: how to best prevent arterial thrombosis. For the current and future pioneers of platelet research an understanding of how we got to where we are today will hopefully allow for a clearer and inspired vision of where we will go next.
Keywords: Platelet, aggregometry, aspirin, history, bleeding time, platelet adhesiveness, light transmittance aggregometry, salicyclates, early medical therapy
Current Drug Targets
Title: Historical Observations on the Discovery of Platelets, Platelet Function Testing and the First Antiplatelet Agent
Volume: 12 Issue: 12
Author(s): Steven R. Steinhubl
Affiliation:
Keywords: Platelet, aggregometry, aspirin, history, bleeding time, platelet adhesiveness, light transmittance aggregometry, salicyclates, early medical therapy
Abstract: An understanding of the historical paths that have lead to our current state of knowledge in the field of platelet studies can be both illuminating and inspiring. Considering that the existence and function of platelets were initially described just barely over 100 years ago it is exciting to recognize how far our knowledge has advanced in such a relatively short period of time. Within 20 years of Giulio Bizzozero's definitive description of blood platelets investigators began to develop tests that could quantitate the relationship between platelets, hemostasis and bleeding, and these tests have continued to be refined ever since. At the same time, and well before the role of platelets and antiplatelet agents in cardiovascular disease was appreciated, several clinicians started using aspirin for the prevention of heart attacks. All three of these paths of research - platelet biology, platelet function testing and antiplatelet therapies - all converge on what is arguably one of the most important questions in clinical medicine today: how to best prevent arterial thrombosis. For the current and future pioneers of platelet research an understanding of how we got to where we are today will hopefully allow for a clearer and inspired vision of where we will go next.
Export Options
About this article
Cite this article as:
R. Steinhubl Steven, Historical Observations on the Discovery of Platelets, Platelet Function Testing and the First Antiplatelet Agent, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635858
DOI https://dx.doi.org/10.2174/138945011797635858 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot Topic Proceedings of the European Society of Cardiology Working Group on Peripheral Circulation Symposium "Cardiometabolic Risk and Vascular Disease – from Mechanisms to Treatment", Rome 3-5 November 2011 (Guest Editor: Francesco Cosentino Associate Guest Editors: Charalambos Vlachopoulos and Francesco Paneni)]
Current Vascular Pharmacology Quantitative Color Doppler Ultrasonography Measurement of Thyroid Blood Flow in Patients with Graves’ Disease
Current Medical Imaging High Sensitivity C-Reactive Protein as a Potential Biomarker of Neuroinflammation in Major Psychiatric Disorders
Current Psychiatry Reviews Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Global Trends of Computational Fluid Dynamics to Resolve Real World Problems in the Contemporary Era
Current Biochemical Engineering (Discontinued) Current Management of Peripheral Vascular Disease: Where is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Red Meat Required for the Prevention of Iron Deficiency Among Children and Adolescents?
Current Pediatric Reviews EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Biomarkers in Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Current Vascular Pharmacology Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery